This study focuses on patients with Higher-risk Myelodysplastic Syndromes, a group of blood disorders where bone marrow does not produce enough healthy blood cells. The study evaluates two different treatment approaches: immediate hematopoietic stem cell transplantation (a procedure where damaged bone marrow is replaced with healthy stem cells) or transplantation after receiving other treatments.
The main treatment being studied is Azacitidine, which is given as an injection under the skin. Other medications that may be used in the study include Fludarabine, Daunorubicin, Busulfan, Cytarabine, and Thiotepa. These medications are given through an intravenous line directly into the bloodstream.
The purpose of this research is to determine whether it is better to perform stem cell transplantation immediately or to first treat patients with medications like Azacitidine or traditional chemotherapy, depending on the number of abnormal cells in their bone marrow. The study will monitor patients’ health and recovery throughout their treatment period and follow-up care.
Italy 
